Five Prime greenshoe exercised in $43.13 million public sale of stock

Jefferies, BMO Capital Markets and Wells Fargo were joint bookrunners

By Devika Patel

Knoxville, Tenn., Feb. 12 - Five Prime Therapeutics, Inc. said the underwriters for its public offering of stock opted to exercise the deal's $5.63 million greenshoe in full, lifting total proceeds to $43.13 million. The deal was announced Jan. 22 and priced for $37.5 million with the greenshoe on Feb. 6.

The company sold 3.45 million common shares at $12.50 per share. The price per share is an 0.87% discount to the Feb. 5 closing share price of $12.61. Of the shares, 450,000 were part of the fully exercised greenshoe.

Jefferies, BMO Capital Markets and Wells Fargo Securities were the joint bookrunning managers.

The clinical-stage biotechnology company is based in South San Francisco, Calif.

Issuer:	Five Prime Therapeutics, Inc.
Issue:	Common stock
Amount:	$43,125,000, including $5,625,000 greenshoe
Shares:	3.45 million
Price:	$12.50
Warrants:	No
Bookrunners:	Jefferies LLC, BMO Capital Markets and Wells Fargo Securities, LLC
Co-manager:	Guggenheim Securities, LLC
Announcement date:	Jan. 22
Pricing date:	Feb. 6
Settlement date:	Feb. 12
Stock exchange:	Nasdaq: FPRX
Stock price:	$12.61 at close Feb. 5
Market capitalization:	$280.42 million

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.